Empowering surgeonsde voir l'invisible

seeing the

invisible

Minimally invasive surgery reduces the sense of touch for surgeons. AstraNICE’s revolutionary fluorescent coating enhances surgeon’s vision to compensate for this loss, enabling real-time visualization of instruments through tissues.

AstraNICE in 5 figures

Revolutionary fluorescent coating

Patents with worldwide coverage

Proofs of concept

30x

Brighter than the current solution (ICG)

60+

Identified surgical applications

A unique technology

NICE, a disruptive technology for minimally invasive surgery

NICE is a patented near-infrared fluorescent coating. It is a polymer containing encapsulated fluorescent molecules applied directly to surgical instruments and devices. This coating significantly improves their visibility during minimally invasive surgery without changing current surgical practices.

Fluorescence Image-Guided Surgery (FIGS)

Open surgery

Minimally invasive surgery

Surgical automation

Fluorescence calibration & quantification

Precision robotic surgery

Augmented reality

Applications

One technology, multiple applications

Fluorescence Image-Guided Surgery (FIGS)

Open surgery

Minimally invasive surgery

Surgical automation

Fluorescence calibration & quantification

Precision robotic surgery

Augmented reality

Surgical instruments

Endoscopic clips

Catheters

Sutures

Implantable devices

Stents

Fiducials

...

Non-health applications

Open surgery

68Md $

CAGR 6.6% (2025-2030)

Minimally invasive surgery

69Md $

CAGR +9.1% (2025-2030)

Robotic surgery

9Md $

CAGR +15.4% (2025-2030)

Source : The Business Research Company

AstraNICE

2015

Need identified by the Scientific Director of IRCAD to increase surgical precision without injecting fluorescent molecules in patients. Research collaboration launched (IRCAD, University of Strasbourg, CNRS) and discovery of the NICE fluorescent coating by the scientific team of UMR CNRS 7021.

2018-2022

SATT CONECTUS investment: validation of the fluorescent polymer's biocompatibility, stability, and resistance to sterilization. Filing of 2 patents with worldwide coverage. Preclinical studies & proofs of concept in pigs and human cadavers.

2022

Market study confirmed strong industry and surgeon interest.

2024

AstraNICE founded.

2025

Fundraising.
Opening of capital to key opinion leaders, experts in minimally invasive and robotic surgery, as well as to the Fondation Force, committed to supporting innovation in healthcare, whose Scientific Council is chaired by Jules Hoffman, Nobel Prize laureate in Medicine.

AstraNICE, our mission

Democratize the practice of minimally invasive surgery by making it more precise and safer.
‍
To make the automation of robotic surgery possible.

AstraNICE is…

Over 60 potential clinical applications

Greater visibility: up to 1 cm through tissue and mucous membranes

Greater precision in surgeons' movements

Better tumor delineation and complete removal

Increased patient comfort and safety

More bed availability (shorter hospital stays)

Increased operating room availability

Lower risk of side effects or allergic reactions in patients (no injection of fluorescent molecules)

Less stress for the surgeon

Fewer iatrogenic injuries (in critical organs located in the surgical area)

Fewer surgical & post-operative risks and complications

Shorter hospital stays

No product injected into the patient

Zero toxicity & risk of fluorescent agents leaking into patients' bodies

astranice, the next steps

2026

First product co-developments with major industry players

2027

Launch of Factory 4.0 project

2028

2nd fundraising round

2030

Robotic surgery

our team

A multidisciplinary team at the intersection of science, industry, and surgery

“Our patented NICE technology is THE future imaging solution for minimally invasive surgery for manufacturers and associations of surgeons. For ever more effective and accurate surgery, for even more comfort and safety for the patient. We are convinced of that.”

/ John Volke

CEO, co-founder of AstraNICE, 25 years of experience in DM & DMDIV in the industry.

“NICE technology currently makes it possible to visualize fluorescent equipment at a depth of 1 cm. Our development program will soon allow for visualization that goes well beyond...”

/ Dr. Andrey Klymchenko

CSO, co-founder of AstraNICE, CNRS Research Director, CNRS, Bioimaging and Pathology Laboratory (UMR 7021 CNRS - University of Strasbourg).
‍

“In the short term, AstraNice's portfolio will address current clinical problems by making medical devices visible through fluorescence imaging. In the long term, AstraNICE will take advantage of artificial intelligence and develop digital solutions that incorporate our NICE technology.”

/ Pr Michele Diana

CMO, co-founder of AstraNICE, Surgeon & Researcher, Head of Surgical Innovation at the Department of Surgery of the University Hospitals of Geneva, Switzerland, Professor of Surgery at the Faculty of Medicine of Geneva, Switzerland.

“Our coating can be used in all types of surgeries and is applicable on all types of substrates (steel, fabric, PVC...). Its field of application is therefore immense for an optimal cost and development time. Not to mention how easy it is to use and implement.”

/ Sandrine Ropp

COO and co-founder of AstraNICE, 20 years of experience in the management of innovative projects in health and R&D for the pharmaceutical industry.

“While human vision is limited to the visible spectrum, AstraNICE technology reveals light that is invisible to the naked eye. The near infrared fluorescent coating that we adapt for the various equipment improves the vision of surgeons by illuminating surgical instruments, critical tissues or organ/tumor boundaries in real time, allowing them to operate with extreme precision and ensure increased patient safety.”

/ Hung Quoc Tran

Biomaterials Engineer, Holder of a Doctoral Thesis in Life Sciences with a specialization in biomaterial chemistry.

Our Partners